Natixis Advisors LLC Makes New Investment in Artivion, Inc. (NYSE:AORT)

Natixis Advisors LLC bought a new stake in Artivion, Inc. (NYSE:AORT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,838 shares of the company’s stock, valued at approximately $310,000.

Other large investors also recently made changes to their positions in the company. Quarry LP grew its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after acquiring an additional 820 shares during the period. Smartleaf Asset Management LLC boosted its position in Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. R Squared Ltd bought a new position in Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the fourth quarter worth about $43,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Artivion in the fourth quarter valued at approximately $78,000. 86.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Needham & Company LLC cut their target price on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $31.40.

Insider Activity at Artivion

In other news, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is owned by corporate insiders.

Artivion Stock Down 1.0 %

NYSE:AORT opened at $24.26 on Friday. The firm has a 50-day simple moving average of $27.58 and a two-hundred day simple moving average of $27.61. The firm has a market cap of $1.02 billion, a P/E ratio of -1,212.80 and a beta of 1.79. Artivion, Inc. has a fifty-two week low of $19.36 and a fifty-two week high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.